SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-019157
Filing Date
2023-05-09
Accepted
2023-05-09 08:05:15
Documents
70
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrv-20230331.htm   iXBRL 10-Q 2558414
2 EX-31.1 acrv-ex31_1.htm EX-31 19446
3 EX-31.2 acrv-ex31_2.htm EX-31 19427
4 EX-32.1 acrv-ex32_1.htm EX-32 13070
5 EX-32.2 acrv-ex32_2.htm EX-32 13053
  Complete submission text file 0000950170-23-019157.txt   9157880

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT acrv-20230331_def.xml EX-101.DEF 267597
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT acrv-20230331_cal.xml EX-101.CAL 52616
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acrv-20230331.xsd EX-101.SCH 58434
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acrv-20230331_lab.xml EX-101.LAB 469699
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acrv-20230331_pre.xml EX-101.PRE 389430
64 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20230331_htm.xml XML 1659671
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41551 | Film No.: 23900066
SIC: 2834 Pharmaceutical Preparations